Piper Sandler raised the firm’s price target on Ardelyx (ARDX) to $9 from $8 and keeps a Neutral rating on the shares. The firm is incrementally positive on the name following Q2 2025 reporting. That said, with management still not committing to Xphozah guidance this year but continuing to guide to $750M in peak U.S. sales before patent expiry, the firm continues to look for a better sense of uptake and the near- and immediate-term outlook for this drug before getting more constructive on the name.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDX:
- Ardelyx Inc. Faces Financial Uncertainty Amid Shifting Trade Policies
- Ardelyx Inc. Q2 2025 Earnings Call Highlights
- Ardelyx price target raised to $14 from $13 at Wedbush
- Ardelyx price target raised to $12 from $11 at Raymond James
- Ardelyx’s Strong Commercial Execution and Growth Prospects Drive Buy Rating